tickrz reports
  
tickrz rank
B
Hologic Inc (HOLX)
Healthcare | Medical Appliances & Equipment
CEO: Stephen P. MacMillan
Employees: NOT AVAILABLE
hologic.com
FACTOR RANKINGSFACTOR SCREENER 
Pure Value Rank203Dividend RankNO DIVIDEND
Moat Rank329Financial Strength Rank185
Growth Rank194Momentum Rank96
DIVIDEND ANALYSIS
Dividend Yield0%
Payout RatioN/A
3 yr Dividend GrowthN/A
VALUATION RATIOS
P/E Ratio15.56x
P/B Ratio4.4x
P/S Ratio4.25x
EV/EBITDA Ratio7.44x
FINANCIAL STRENGTH
Piotroski F-Score9
Debt-to-Equity118%
Interest Coverage9.28x
MOAT
ROE32.65%
ROIC17.34%
Net Margin11.68%
GROWTH
5 yr EPS Growth14.48%
5 yr SPS Growth9.62%
5 yr BPS Growth-7.18%
Hologic Inc's stock has climbed 28% over the last year, earning it a strong Momentum Rank
 tickrz summary
Hologic Inc receives a B ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
 value
 pure value ranking Warren Buffett ranking
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Hologic Inc's valuation score is comprised of a P/E ratio of 15.6x, a P/B ratio of 4.4x, a P/S ratio of 4.3x, and an EV/EBITDA ratio of 7.4x. Hologic Inc ranks 203 out of the S&P 500 constituents on valuation--a relatively average score.Hologic Inc ranks 134 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a strong score, meaning it ranks highly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Hologic Inc warrants further investigation.

 quality
 moat financial strength
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is weak. Its position within the Healthcare sector appears to be weak. Either the dynamics of its sector place it in a difficult position or management's executition is to blame for its disappointing performance.Hologic Inc has a Piotroski F Score of 9 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 9.28x, a debt/equity ratio of 118% and a Moat Rank of 329 translate to an average Financial Strength score.


 momentum
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 28.28% over the last 12 months. This performance is strong compared to other stocks in the S&P 500, earning it a rank of 96. Hologic Inc's strong 12 month stock performance will appeal to momentum investors.

 yield
 value + yield
Hologic Inc currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

 growth
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value produce an average score. 14.5% 5 year annualized EPS growth, 9.6% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of -7.2% combine to produce this average score.

Hologic Inc (HOLX)
Healthcare | Medical Appliances & Equipment
CEO: Stephen P. MacMillan
Employees: NOT AVAILABLE
hologic.com


tickrz rank
B

VALUATION RATIOS
P/E Ratio15.56x
P/B Ratio4.4x
P/S Ratio4.25x
EV/EBITDA Ratio7.44x
DIVIDEND ANALYSIS
Dividend Yield0%
Payout RatioN/A
3 yr Dividend GrowthN/A
FINANCIAL STRENGTH
Piotroski F-Score9
Debt-to-Equity118%
Interest Coverage9.28x
MOAT
ROE32.65%
ROIC17.34%
Net Margin11.68%
GROWTH
5 yr EPS Growth14.48%
5 yr SPS Growth9.62%
5 yr BPS Growth-7.18%

TICKRZ RANK
Hologic Inc receives a B ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Hologic Inc's valuation score is comprised of a P/E ratio of 15.6x, a P/B ratio of 4.4x, a P/S ratio of 4.3x, and an EV/EBITDA ratio of 7.4x. Hologic Inc ranks 203 out of the S&P 500 constituents on valuation--a relatively average score.

WARREN BUFFETT RANKING
Hologic Inc ranks 134 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a strong score, meaning it ranks highly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Hologic Inc warrants further investigation.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is weak. Its position within the Healthcare sector appears to be weak. Either the dynamics of its sector place it in a difficult position or management's executition is to blame for its disappointing performance.

FINANCIAL STRENGTH
Hologic Inc has a Piotroski F Score of 9 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 9.28x, a debt/equity ratio of 118% and a Moat Rank of 329 translate to an average Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 28.28% over the last 12 months. This performance is strong compared to other stocks in the S&P 500, earning it a rank of 96. Hologic Inc's strong 12 month stock performance will appeal to momentum investors.

VALUE + YIELD
Hologic Inc currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value produce an average score. 14.5% 5 year annualized EPS growth, 9.6% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of -7.2% combine to produce this average score.